In the Tech News Spy article, “Tempus, Eric Lefkofsky, and the Rise of Data-Enabled Precision Medicine” Heidi Harris discusses the advances in cancer treatment made by Lefkofksy’s company, Tempus.
The National Cancer Institute shows that nearly 14.5 million U.S. citizens were diagnosed with cancer in 2014 and they predict the number to grow to over 19 million by 2024. Yet, cancer patients have traditionally found that despite the technological improvement in other industries, the healthcare industry was lacking in providing digital technology and data collection to healthcare providers.
Tempus seeks to change that. The company seeks to create a paradigm shift in the way cancer is analyzed by medical professionals. Tempus created software to analyze physician notes and free text fields in order to obtain and analyze the data. By including optical character recognition and natural language processing, the software is able to transform the notes into usable data that is structured to revamp cancer treatment and care and learn more about Eric Lefkofksy.
Tempus will also use genomic information. By using human genome sequencing the company will be able to analyze the individual’s molecular information in order to individualize treatment. Tempus allows physicians and specialists to understand their patients at a molecular level by providing deep analytics of molecular and clinical data to provide personalized treatment options and more information click here.
The validation for specialists is created through a new cell-culture technology. It provides evaluation of therapies in synthetic and animal models with detailed reporting so the doctors can have actionable insights into the patient’s treatment. The information is constantly updated and is always available providing doctors with an immediate insight and deeper understanding of what medicines work with different types of molecular compositions
This data-enabled medicine provides more precision through technologies such as the Tempus platform. It will allow the physicians to accurately match cancer patients with the appropriate and most effective treatment.
Lefkosky began Tempus because of his personal experience. He discovered the lack of data provided to specialists when his wife was seeking cancer treatment and he created the company to resolve that lack.
Eric Lefkofksy is also serial entrepreneur. He started various companies like Groupon, Echo Global Logistics, InnerWorkings, and Uptake. He currently lives in Chicago with his wife, Elizabeth.